--- title: "Onshoring pharma: tech transfer to a US site | QLogixCMC" description: "Bringing a product to a new US site: gap analysis, qualification, method transfer, engineering and PPQ batches and PAI readiness, with an interactive timeline." url: https://qlogixcmc.com/blog/onshoring-drug-manufacturing-tech-transfer markdown: https://qlogixcmc.com/blog/onshoring-drug-manufacturing-tech-transfer.md updated: 2026-10-20 publisher: "QLogixCMC (QLogixCMC LLC)" language: en-US --- Technology transfer 20 October 2026 3 min readBy QLogixCMC # Onshoring drug manufacturing: the tech transfer and validation path to a US site Onshoring moves a product's manufacturing to a site that has not made it before. The path is the same every time: a gap analysis between the sending and receiving sites, qualification of the facility and the equipment, transfer of the analytical methods, engineering batches, process performance qualification and a pre-approval inspection. The order in which those run decides whether the site is ready in a year or in two. ## Why it is on every agenda The push to make more medicines in the United States, from policy, from supply security and from customers asking where a product is made, has sponsors moving products to domestic sites and CDMOs adding capacity to receive them. The receiving site is often new, or new to the product, and the transfer lands on a quality and CMC team that is already busy. For an approved product, a new manufacturing site is a post-approval change. In the United States it normally goes to FDA as a prior approval supplement, and FDA may inspect the site before approving it. The transfer plan therefore has two customers from the start: the receiving site, which has to make the product, and the agency, which has to be shown that the product is the same. ## The critical path - Gap analysis between sending and receiving sites: process, equipment and scale, materials, methods, procedures and people, with each gap given an owner and a closure plan - Facility, utilities and equipment qualification where the suite is new, or a documented assessment where it is already qualified for similar products - Analytical method transfer with comparative testing, so the receiving laboratory's results can be trusted before the first batch is tested - Engineering batches that find the equipment and scale differences before they appear in a PPQ batch - Process performance qualification, with the number of batches justified from the process knowledge and its variability rather than taken as three by habit - Stability on the PPQ batches, the supplement, and a site that can show an inspector its records on request Interactive How the sequence sets the date Receiving suite already qualified Transfer analytical methods in parallel with qualification Prepare the supplement and PAI while PPQ runs Engineering batches1 PPQ batches3 16.1months to PAI-ready 3 PPQ batches after 1 engineering batch. - On the critical path - Run in parallel Illustrative planning durations. The gap analysis fixes the order; the biggest savings come from starting method transfer while the suite is qualified and from preparing the inspection while PPQ runs. Zero engineering batches shortens the plan and makes the first PPQ batch the first batch at scale, which is where deviations happen. ## What makes the timeline slip - Method transfer started after qualification instead of alongside it, so the laboratory is the last thing ready - Equipment differences discovered during a PPQ batch rather than in an engineering run - No comparability protocol agreed with the sending site, so the data from the two sites cannot be compared when the supplement is written - A PPQ batch count with no justification on file, which an inspector reads as a process nobody understands - Documents written for the submission rather than from the batch records, so the narrative and the evidence disagree ## How QLogixCMC helps QLogixCMC engineers run the gap analysis with both sites, write the transfer and comparability protocols, and are on the receiving site's floor for qualification, engineering batches and PPQ execution. The supplement, the method transfer reports and the PAI readiness work run remotely or on site as the deliverables require, and the quality unit of the receiving site approves every protocol and report. ## Related services - [CMC and regulatory](https://qlogixcmc.com/services/cmc-and-regulatory) - [Validation and computer software assurance](https://qlogixcmc.com/services/validation-and-csa) - [Inspection readiness and compliance remediation](https://qlogixcmc.com/services/inspection-readiness) ## Facing this at your site? Bring the numbers from the figure above. We will say what we would assess first and what we would leave alone. [Request a meeting](https://qlogixcmc.com/contact) ## Questions this post answers ### How many PPQ batches does a transfer need? FDA's process validation guidance does not set a number. The count is justified from what is known about the process and its variability. Three is a common starting point, not a rule: a variable process or a new scale may need more, and a well-characterized process transferred with engineering batches may justify fewer, with the reasoning on file. ### Does moving an approved product to a new site need FDA approval? In the United States a new manufacturing site for an approved drug is normally a prior approval supplement, and FDA may inspect the site before approving it. The comparability protocol, the supplement and the inspection readiness are part of the transfer plan from the first week. ### Can method transfer run before the suite is qualified? Yes, and it should. Analytical method transfer needs the receiving laboratory, its instruments and its analysts, not the manufacturing suite. Running it alongside qualification takes months off the plan. ## More from the blog - [AI and digital quality · 13 October 2026AI in the GMP quality system: what Annex 22 and your next inspector will ask](https://qlogixcmc.com/blog/ai-in-gmp-quality-system-annex-22) - [Sterile manufacturing · 6 October 2026Annex 1 three years on: the contamination control strategy inspectors now read first](https://qlogixcmc.com/blog/annex-1-contamination-control-strategy) - [Validation · 29 September 2026Computer software assurance: how much testing does your system actually need?](https://qlogixcmc.com/blog/computer-software-assurance-how-much-testing) ## Talk it through with someone who has run a plant Bring your backlog, your submission timeline or the Form 483. We will tell you plainly what we would do first, what it would take, and what we would leave alone. [Request a meeting](https://qlogixcmc.com/contact)[Email us](mailto:contact@qlogixcmc.com) In the first meeting we cover - What is on your mind: a backlog, a submission, a validation program, an inspection date or a system that is not working - What we would assess first, and what we would leave alone - Whether an engineer on your site, a fixed-scope assessment or a defined deliverable is the right way to start ## More from QLogixCMC - [AI in the GMP quality system: what Annex 22 and your next inspector will ask](https://qlogixcmc.com/blog/ai-in-gmp-quality-system-annex-22.md): EU GMP Annex 22: what the draft asks of AI in GMP, the questions inspectors already ask, and an interactive look at AI-drafted deviation investigations. - [Annex 1 three years on: the contamination control strategy inspectors now read first](https://qlogixcmc.com/blog/annex-1-contamination-control-strategy.md): What the revised EU GMP Annex 1 asks of sterile manufacturers, where inspections find gaps, and an interactive EM trend that catches a contamination shift early. - [Computer software assurance: how much testing does your system actually need?](https://qlogixcmc.com/blog/computer-software-assurance-how-much-testing.md): FDA's CSA approach scales validation testing to the risk of each function. What changed from CSV, how to apply it, and an interactive estimate of the effort saved. - [Comparability for cell, gene and mRNA therapies: proving a process change left the product unchanged](https://qlogixcmc.com/blog/cell-gene-mrna-therapy-comparability.md): Why advanced therapies change process so often, what ICH Q5E and FDA's CGT guidance expect, and an interactive study showing why lot count decides the result. - [Why 21 CFR 211.192 stays the most-cited observation, and how a backlog really comes down](https://qlogixcmc.com/blog/211-192-investigations-backlog.md): What 211.192 requires, the three ways investigations fail, and an interactive burn-down showing when a deviation backlog clears and which records go first. - [QLogixCMC home](https://qlogixcmc.com/index.md): CMC consulting for biotech, pharma and CDMOs: Module 3 from IND to BLA, control strategy, GMP quality systems, validation, CAPA and FDA inspection readiness. - [Services](https://qlogixcmc.com/services.md): QLogixCMC services, on site or remote: CMC and regulatory, quality systems, validation and CSA, investigations and CAPA, inspection readiness, GxP systems and AI. - [Request a meeting](https://qlogixcmc.com/contact.md): Talk to QLogixCMC about a CMC submission, your quality system, validation, an investigation backlog or an FDA inspection. We reply to set up a time. - [llms.txt: a summary of the site for AI assistants](https://qlogixcmc.com/llms.txt) - [Site map](https://qlogixcmc.com/sitemap.md) --- Source: https://qlogixcmc.com/blog/onshoring-drug-manufacturing-tech-transfer Cite this page as https://qlogixcmc.com/blog/onshoring-drug-manufacturing-tech-transfer QLogixCMC · contact@qlogixcmc.com · +17146639012